, Volume 25, Issue 2, pp 90–94 | Cite as

IL-1β and IL-6 in community-acquired pneumonia: Bacteremic pneumococcal pneumonia versusMycoplasma pneumoniae pneumonia

  • D. Lieberman
  • S. Livnat
  • F. Schlaeffer
  • A. Porath
  • S. Horowitz
  • Rachel Levy


Interleukin-1β (IL-1β) and interleukin-6 (IL-6) levels in 20 patients with bacteremicStreptococcus pneumoniae community-acquired pneumonia (CAP) were compared with these cytokine levels in 20 patients withMycoplasma pneumoniae CAP. All 40 patients survived hospitalization and underwent a follow-up examination one month later. Serum IL-1β and IL-6 levels were determined by the enzyme immunoassay (EIA) method using commercial kits. In the acute phase of CAP, IL-6 levels were significantly higher in theS. pneumoniae group (p=0.014), while IL-1β levels were higher in theM. pneumoniae group (p=0.046). In the convalescence phase, the two cytokines were detected in a considerable number of patients in both groups. In this phase, only the level of IL-1β was significantly higher in theM. pneumoniae group than in theS. pneumoniae group (p=0.03). We conclude that the levels of IL-1β and IL-6 are different between patients withS. pneumoniae-CAP andM. pneumoniae-CAP during the acute phase. In the convalescence phase, cytokine levels remain high in some of the CAP patients, but a significant difference between the groups exists only for IL-1β. Further studies are required.


Public Health Enzyme Internal Medicine Infectious Disease Pneumonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bartlett, J. G., Mundy, L. M. Community-acquired pneumonia. N. Engl. J. Med. 333 (1995) 1618–1624.CrossRefPubMedGoogle Scholar
  2. 2.
    Waage, A., Brandtzaeg, P., Halsteusen, A., Kierulf, P., Espevik, T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J. Exp. Med. 169 (1989) 333–338.CrossRefPubMedGoogle Scholar
  3. 3.
    Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey III, T. J., Zentella, A., Albert, J. D., Shires, G. T., Cerami, A. Shock and tissue injury induced by recombinant human cachectin. Science 234 (1986) 470–474.PubMedGoogle Scholar
  4. 4.
    Movat, H. Z., Cybulsky, M. I., Colditz, I. G., Chan, M. K., Dinarillo, C. A. Acute inflammation in gram-negative infection: endotoxin, interleukin-1, tumor necrosis factor, and neutrophils. Fed. Proc. 46 (1987) 97–104.PubMedGoogle Scholar
  5. 5.
    Demling, R. H. The role of mediators in human ARDS. J. Crit. Care 3 (1988) 56–72.CrossRefGoogle Scholar
  6. 6.
    Moussa, K., Michie, H., Cree, I. A., McCafferty, A. C., Winter, J. H., Dhillon, D. P., Stephens, S., Brown, R. A. Phagocyte function and cytokine production in community acquired pneumonia. Thorax 49 (1994) 107–111.PubMedGoogle Scholar
  7. 7.
    Pinsky, M. R., Vincent, J. L., Deviere, J., Alegre, M., Kahn, R. J., Dupont, E. Serum cytokine levels in human septic shock. Chest 103 (1993) 565–575.PubMedGoogle Scholar
  8. 8.
    Casey, L., Balk, R. A., Bone, R. C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 119 (1993) 771–778.PubMedGoogle Scholar
  9. 9.
    Hack, C. E., De Groot, E. R., Felt-Bersma, R. J., Nuijens, J. H., Strack Van Schijndel, R. J., Eerenberg-Belmer, A. J. M., Thijs, L. G., Aarden, L. A. Increased plasma levels of interleukin-6 in sepsis. Blood 74 (1989) 1704–1710.PubMedGoogle Scholar
  10. 10.
    Lieberman, D., Schlaeffer, F., Boldur, I., Lieberman, D., Horowitz, S., Friedman, M. G., Leinonen, M., Horovitz, O., Manor, E., Porath, A. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 51 (1996) 179–184.PubMedGoogle Scholar
  11. 11.
    Knaus, W. A., Zimmerman, J. E., Wagner, D. P., Draper, E. A., Lawrence, D. E. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit. Care Med. 9 (1981) 591–597.PubMedGoogle Scholar
  12. 12.
    Calandra, T., Gerain, J., Heumann, D., Baumgartner, J. D., Glauser, M. P. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am. J. Med. 91 (1991) 23–29.CrossRefPubMedGoogle Scholar
  13. 13.
    Calandra, T., Baumgartner, J. D., Grau, G. E., Wu, M. M., Lambert, P. H., Schellenkens, J., Verhoef, J., Glauser, M. P. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α and interferon-γ in the serum of patients with septic shock. J. Infect. Dis. 161 (1990) 982–987.PubMedGoogle Scholar
  14. 14.
    Damas, P., Reuter, A., Gysen, P., Demonty, J., Lamy, M., Franchimont, P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit. Care Med. 17 (1989) 975–978.PubMedGoogle Scholar
  15. 15.
    Helfgott, D. C., Tatter, S. B., Santhanam, U., Clarick, R. H., Bhardwaj, N., May, L. T., Sehgal, P. B. Multiple forms of IFN-β2/II-6 in serum and body fluids during acute bacterial infection. J. Immunol. 142 (1989) 948–953.PubMedGoogle Scholar
  16. 16.
    Waage, A., Halstensen, A., Espevik, T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet i (1987) 355–357.CrossRefGoogle Scholar
  17. 17.
    Marik, P., Kraus, P., Sribante, J., Havlik, I., Lipman, J., Johnson, D. W. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 104 (1993) 389–392.PubMedGoogle Scholar
  18. 18.
    Beutler, B., Krochin, N., Milsark, I. W., Luedke, C., Cerami, A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232 (1986) 977–980.PubMedGoogle Scholar
  19. 19.
    Sheppard, B. C., Fraker, D. L., Norton, J. A. Prevention and treatment of endotoxin and sepsis lethality with recombinant tumor necrosis factor. Surgery 106 (1989) 156–162.PubMedGoogle Scholar
  20. 20.
    Preiser, J. C., Schmartz, D., Van der Linden, P., Content, J., Vanden Bussche, P., Buurman, W., Sebald, W., Dupont, E., Pinsky, M. R., Vincent, J. L. Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog. Cytokine 3 (1991) 1–4.CrossRefPubMedGoogle Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1997

Authors and Affiliations

  • D. Lieberman
    • 1
  • S. Livnat
    • 2
  • F. Schlaeffer
    • 2
  • A. Porath
    • 2
  • S. Horowitz
    • 3
  • Rachel Levy
    • 4
  1. 1.Pulmonary Unit, Div. of Internal MedicineBen-Gurion University of the NegevBeer-ShevaIsrael
  2. 2.Div. of Internal MedicineBen-Gurion University of the NegevBeer-ShevaIsrael
  3. 3.National Center for MycoplasmaBen-Gurion University of the NegevBeer-ShevaIsrael
  4. 4.Infectious Diseases Laboratory, Soroka Medical Center of Kupat Holim Klalit and the Faculty of Health SciencesBen-Gurion University of the NegevBeer-ShevaIsrael

Personalised recommendations